Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Income from Continuing Operations of 50003000.0 for Q1 2026, down 144.3% year-over-year from 112879000.0 in Q1 2025, and up 19.91% quarter-over-quarter from 62436000.0 in Q4 2025.
Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 50003000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 144.3% year-over-year to 50003000.0; the TTM figure through Mar 2026 stood at 174269000.0 (down 478.76% YoY), while the FY2025 annual figure was 204286000.0, down 67.55% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 50003000.0, up from 62436000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 112879000.0 in Q1 2025, with the low at 162769000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 27174000.0 (2023), against an average of 36375588.24.
- Peak annual rise in Income from Continuing Operations reached 527.99% in 2025, while the deepest fall reached 323.5% in 2025.
- Stoke Therapeutics' Income from Continuing Operations stood at 124548000.0 in 2022, then tumbled by 30.69% to 162769000.0 in 2023, then jumped by 90.94% to 14743000.0 in 2024, then plunged by 323.5% to 62436000.0 in 2025, then increased by 19.91% to 50003000.0 in 2026.
- Business Quant data shows STOK's Income from Continuing Operations at 50003000.0 in Q1 2026, 62436000.0 in Q4 2025, and 38347000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -61.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.62 Mn |
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -62.44 Mn |
| Sep 30, 2025 | -38.35 Mn |
| Jun 30, 2025 | -23.48 Mn |
| Mar 31, 2025 | 112.88 Mn |
| Dec 31, 2024 | -14.74 Mn |
| Sep 30, 2024 | -26.43 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -26.37 Mn |
| Dec 31, 2023 | -162.77 Mn |
| Sep 30, 2023 | -27.17 Mn |
| Jun 30, 2023 | -37.09 Mn |
| Mar 31, 2023 | -24.71 Mn |
| Dec 31, 2022 | -124.55 Mn |
| Sep 30, 2022 | -29.28 Mn |
| Jun 30, 2022 | -32.19 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -90.70 Mn |
| Sep 30, 2021 | -25.27 Mn |